Skip to main content

Table 1 Baseline characteristics from the training and validation datasets

From: Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study

  Training Validation P-value
Age, years (range) 60.4 (36–88) 60.4 (31–84) 0.331
Sex, n (%)    0.045
 Male 164 (75.2%) 144 (66.1%)  
 Female 54 (24.8%) 74 (33.9%)  
Smoking history, n (%)    0.101
 Never 112 (51.4%) 130 (59.6%)  
 Former/current 106 (48.6%) 88 (40.4%)  
Metastatic sites, n (%)    0.233
 1–2 208 (95.4%) 201 (92.2%)  
 3 10 (4.6%) 17 (7.8%  
Classification, n (%)    0.690
 Synchronous 137 (62.8%) 142 (65.1%)  
 Metachronous 81 (37.2%) 76 (34.9%)  
Pathology, n (%)    0.616
 Adenocarcinoma 164 (75.2%) 171 (78.4%)  
 Non-adenocarcinoma 47 (21.6%) 45 (20.6%)  
 Unknown 7 (3.2%) 2 (1.0%)  
EGFR status, n (%)    0.911
 Negative 110 (50.5%) 107 (49.1%)  
 Positive 77 (35.3%) 82 (37.6%)  
 Unknown 31 (14.2%) 29 (13.3%)  
T stage, n (%)    0.851
 T0–2 149 (68.3%) 155 (71.1%)  
 T3–4 67 (30.7%) 61 (27.9%)  
N stage, n (%)    0.282
 N0 49 (22.5%) 63 (28.9%)  
 N+ 169 (77.5%) 155 (71.1%)  
LCT    0.968
 Surgery 17 (7.8%) 15 (6.9%)  
 Radiotherapy 79 (36.2%) 80 (36.7%)  
 Both 4 (1.8%) 3 (1.4%)  
 Neither 118 (54.2%) 120 (55.0%)  
Total 218 218  
  1. EGFR epidermal growth factor receptor; LCT local consolidative therapy